Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 188.8.131.52) - Pipeline Review, H1 2018
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 184.108.40.206) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent.
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 220.127.116.11) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Oncology, Hematological Disorders, Dermatology, Gastrointestinal, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Autoimmune Disorders, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Peripheral T-Cell Lymphomas (PTCL), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, B-Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergies, Alzheimer's Disease, Anaphylactic Shock, Arthritis, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Urticaria Or Hives, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Kidney Transplant Rejection, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE) and Systemic Lupus Erythematosus.
The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook